“…Some modifications in the original criteria were observed in most of the studies. Inclusion of subjects under pharmacological treatment for systemic arterial hypertension, dyslipidemia and diabetes mellitus was generally accepted as alternatives for the need of identifying high blood pressure, high triglyceride, low HDL levels or high fasting glucose during clinical and laboratory assessment [ 13 , 14 , 17 , 20 – 24 , 26 , 28 , 29 , 32 , 33 , 35 , 37 ]. Specifically, a few studies included the use of antihypertensive and antidiabetic medications, but not of lipid-lowering drugs, as indicators of metabolic risk [ 15 , 16 , 18 , 27 , 34 , 36 ].…”